ArticleHaematologica2019
Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Use of the Split Luciferase Complementation Assay to Identify Novel Small Molecules That Disrupt Essential Protein-Protein Interactions of Viruses.Biomolecules · 2025Article
- Talazoparib and radiation enhance the senolytic efficacy of venetoclax in therapy-induced senescent triple-negative breast cancer cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Article
- Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease.Scientific reports · 2025Article
- Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment.Biomarkers in medicine · 2025Review
- Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement.BMC cancer · 2024Article
- Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.Nature communications · 2022Article
- Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.Hematological oncology · 2022Article
- Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.Annals of hematology · 2021Article
- CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas WithFrontiers in oncology · 2021Article
- Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials.Journal of blood medicine · 2021Review
- Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Acta pharmaceutica Sinica. B · 2020Review
- Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?Cancers · 2020Review
- Relative quantification of BCL2 mRNA for diagnostic usage needs stable uncontrolled genes as reference.PloS one · 2020Observational
- Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.International journal of molecular sciences · 2019Article
- Drug therapy for double-hit lymphoma.Drugs in context · 2019Review
- New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies.F1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The so-called "double-hit" and "double-protein-expression" lymphoma with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.